Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gilead Sciences' : Trademark Application for "LEAP EDUCATION AND ACCESS PROGRAM" Filed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 11:57pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "LEAP EDUCATION AND ACCESS PROGRAM" by Gretchen R. Stroud, representing Gilead Sciences. This application was made available to the public on September 25, 2017 (see also Pharmaceutical Companies).

The serial number for this application is 85086605.

The international trademark goods and services class codes for this trademark application are 035 and 044. The applicant indicates that "Color is not claimed as a feature of the mark. The mark consists of a swirl design above the words 'LEAP EDUCATION AND ACCESS PROGRAM'."

As submitted by the applicant, this trademark application relates to the following goods and services:

• Assisting patients in enrolling in pharmaceutical reimbursement programs;

• Providing health information, namely, providing information about the treatment of pulmonary arterial hypertension.

The owner/registrar information for this application is: Gretchen R. Stroud, Gilead Sciences, 333 Lakeside Dr, Foster City, CA 94404-1147.

Keywords for this news article include: Pharmaceutical Companies, Trademarks, Gilead Sciences.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
07/13GILEAD SCIENCES : to Release Second Quarter 2018 Financial Results on Wednesday,..
BU
07/13GILEAD SCIENCES : Public Citizen Issues Statement on OMB Associate Director Grog..
AQ
07/12GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead'..
AQ
07/12GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Yescarta® axicabtage..
AQ
07/12GILEAD SCIENCES : New Documents Raise Concerns About Potential Conflict of Inter..
AQ
07/11GILEAD SCIENCES : Michael Amoroso to Join Kite as Senior Vice President and Head..
AQ
07/11GILEAD SCIENCES : Two pre-grant patent oppositions filed on Gileads Hepatitis C ..
AQ
07/11GILEAD SCIENCES : Planned Parenthood Announces New Phase of HIV Prevention Initi..
AQ
07/11GILEAD SCIENCES : Hepatitis c medicines face pre-grant patent oppositions
AQ
07/10GILEAD SCIENCES : Gileads senior clinical research director joins Nimbus to help..
AQ
More news
News from SeekingAlpha
12:04a46 Nasdaq 'Safer' Dividend Net Gains Led By Lam, Western, Broadcom, Vodafone,.. 
07/16Your 52 Top Yield, Upside, & Net Gain NASDAQ Stocks For July 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/14STOCKS TO WATCH : Prime Time In Retail 
07/12GILEAD : Cheap Valuation For Great Pipeline 
Financials ($)
Sales 2018 20 819 M
EBIT 2018 10 765 M
Net income 2018 6 422 M
Debt 2018 13 022 M
Yield 2018 2,94%
P/E ratio 2018 15,64
P/E ratio 2019 14,27
EV / Sales 2018 5,46x
EV / Sales 2019 5,53x
Capitalization 101 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,0 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.61%9 250
SAREPTA THERAPEUTICS INC150.58%9 136